Exocrine Pancreatic Insufficiency Clinical Trials

Find Exocrine Pancreatic Insufficiency Clinical Trials Near You

A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants With Exocrine Pancreatic Insufficiency- EPIC

Status: Recruiting
Location: See all (39) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The purpose of this study is to measure the safety and explore the efficacy of 4 different doses of the new lipase NHS7108 in participants with EPI. In this study, all participants will take NHS7108 daily for 14 days and a matching dose of standard-of-care, pancrelipase (Zenpep®) for 14 days according to Treatment Sequence assignment. Both NHS7108 and Zenpep® are oral capsules that will be taken with each of the daily 3 meals and 2 snacks. Participants will interrupt all of their usual pancrelipase/pancreatin treatment for up to 8 days during screening and for the entire 2 treatment periods, where participants will take either the new lipase NHS7108 or a matching dose of the standard-of-care pancrelipase (Zenpep®). Participants will be asked to stay in a setting that allows controlled diet and 72-hour stool collection for approximately 7 days during the screening period and again for approximately 7 days at the end of each treatment period. During these 3 supervised periods, participants will receive a standardized diet with a predefined amount of fat and protein, stools will be collected in special containers and during the last day of the treatment period, blood samples will be obtained to measure fat absorption. These are essential to ensure valid assessment of participants' fat and protein absorption. Outside the 3 supervised periods, participants will be provided with guidelines and recommendations to create their own home-controlled meals and snacks according to their preferences for the remainder of the study duration. Number of Participants: The aim is to have 56 participants completing the study. Assuming approximately 14% drop-out rate, approximately 66 participants will be randomized to study intervention. Study Arms and Duration: The total study duration for each participant will be about 100 days (approximately 14 weeks), including: * A screening period of up to approximately 28 days (might be extended up to a total of 56 days) prior to the first dose administration. * A crossover treatment period (2 treatment periods: approximately 14 days each, with no washout in between). For each treatment period, study intervention will be administered 5 times a day (with 3 main meals and 2 snacks). After completion of Treatment Period 1, the participant will receive and start the new treatment for Treatment Period 2. * An end of treatment/early discontinuation visit within approximately 7 days of the last study intervention dose. * An end-of-study safety follow-up visit at 14 (±2) days after the last dose administration. Very low dose group: 10 mg NHS7108 (approximately 25,000 LU)/main meal and snack; 25,000 LU Zenpep/main meal and snack (50 mg NHS7108 \[approximately 125,000 LU\] per day; 125,000 LU Zenpep per day) Low dose group: 20 mg NHS7108 (approximately 50,000 LU)/main meal and 10 mg NHS7108 (approximately 25,000 LU)/snack; 50,000 LU Zenpep/main meal and 25,000 LU Zenpep/snack (80 mg NHS7108 \[approximately 200,000 LU\] per day; 200,000 LU Zenpep per day) Medium dose group: 40 mg NHS7108 (approximately 100,000 LU)/main meal and 20 mg (approximately 50,000 LU) NHS7108/snack; 100,000 LU Zenpep/main meal and 50,000 LU Zenpep/snack (160 mg \[approximately 400,000 LU\] NHS7108 per day; 400,000 LU Zenpep per day) High dose group: 60 mg NHS7108 (approximately 150,000 LU)/main meal and 30 mg NHS7108 (approximately 75,000 LU)/snack; 150,000 LU Zenpep/main meal and 75,000 LU Zenpep/snack (240 mg NHS7108 \[approximately 600,000 LU\] per day; 600,000 LU Zenpep per day). The dose for participants \< 60 kg who are assigned to the high dose group will need to be weight-adjusted to ensure that they receive no more than 10,000 LU/kg/day.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: f
View:

• Participant is a male or female between 18 to 85 years of age, inclusive, at the time of signing the informed consent.

• Participants with clinically confirmed\* chronic established (not due to a transient clinical diagnosis, i.e., acute pancreatitis) EPI and with a clinical indication for PERT.

• CFA off PERT of \<80% at screening

• Normal body mass index (BMI) by age and sex to ensure participant's EPI is adequately controlled in the opinion of the investigator (BMI of at least 17.0 and no greater than 35.0 kg/m²)

• Standard-of-care medications are allowed (antibiotics, mucolytic agents, aerosols, antacids), if on stable doses for at least 1 month prior to baseline CFA and CNA assessments and must not be altered in dose or stopped during the study.

• Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators are allowed if on stable doses for at least 3 months prior to randomization. Participants should not start taking CFTR modulators during the duration of the study.

• Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

• Male Participants:

⁃ Non-sterilized male participants are eligible to participate if they agree to one of the following starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up: Must agree to stay abstinent (where abstinence is the preferred and usual lifestyle of the participant), OR male participants with a female partner of childbearing potential must agree to use highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method). Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration. These requirements also apply to participants in a same sex relationship.

⁃ Male participants must agree not to donate sperm starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up.

• Female Participants:

⁃ Female participants of childbearing potential (as defined in Appendix 4) are eligible to participate if they meet the following criteria: Agree not to become pregnant during the clinical study period and until the end-of-study safety follow-up. Have a negative serum pregnancy test at screening and a negative urine pregnancy test at Day 1. If heterosexually active, must agree to consistently use a form of highly effective birth control, in combination with a barrier method starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up, OR agree to stay abstinent (where abstinence is the preferred and usual lifestyle of the participant), starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up. These requirements do not apply to participants in a same sex relationship.

⁃ Female participants of nonchildbearing potential are eligible to participate if one of the following conditions apply: Must have a confirmed clinical history of sterility (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, as confirmed by review of the participant's medical records, medical examination, or medical history interview). Must be postmenopausal as defined as: amenorrhea for at least 1 year prior to screening and a laboratory confirmed serum follicle-stimulating hormone (FSH) level ≥ 40 mIU/mL. Female participants on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use 1 of the non-estrogen hormonal highly effective contraception methods from screening until at and continuing throughout the clinical study period, and until the end-of-study safety follow-up if they wish to continue their HRT during the study.

⁃ Female participants must agree not to donate ova starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up.

⁃ For WOCBP only, serum pregnancy test will be performed at screening and urine pregnancy tests will be performed at the timepoints outlined in the SoA.

⁃ The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.

• Participants are capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

• Participants agree not to participate in another interventional study while participating in the study.

Locations
United States
Arkansas
University of Arkansas for Medical Sciences Hospital - University
NOT_YET_RECRUITING
Little Rock
Arizona
HonorHealth Research Institute
NOT_YET_RECRUITING
Scottsdale
California
Cedars Sinai Medical Center - Inflammatory Bowel Disease Ctr
NOT_YET_RECRUITING
Los Angeles
Keck Hospital of USC
NOT_YET_RECRUITING
Los Angeles
Florida
Omnicure Clinical Research
NOT_YET_RECRUITING
Doral
Advent Health Medical Group
NOT_YET_RECRUITING
Orlando
Kansas
Johnson County Clin-Trials (JCCT)
RECRUITING
Lenexa
Maryland
Johns Hopkins Medicine - Pulmonary and Critical Care
NOT_YET_RECRUITING
Baltimore
Montana
Billings Clinic Hospital - Public
NOT_YET_RECRUITING
Billings
Ohio
University Hospitals Cleveland Medical Center/Rainbow Babies & Children's Hospital
NOT_YET_RECRUITING
Cleveland
The Ohio State University College of Medicine (OSUCOM)
NOT_YET_RECRUITING
Columbus
Oklahoma
University of Oklahoma Health Sciences Center - Pediatrics Hospital - University
NOT_YET_RECRUITING
Oklahoma City
Pennsylvania
Penn State Health
RECRUITING
Hershey
Tennessee
Vanderbilt University Medical Center - Pulmonary Hospital - University
NOT_YET_RECRUITING
Nashville
Other Locations
Bulgaria
Medical Center Medconsult Pleven, Lovech branch
NOT_YET_RECRUITING
Lovech
Medical Center Medconsult Pleven
NOT_YET_RECRUITING
Pleven
MC Hipokrat-N - Gastroenterology
NOT_YET_RECRUITING
Plovdiv
Medical Center Excelsior base 3
NOT_YET_RECRUITING
Sofia
Hungary
MH Egészségügyi Központ - Gasztroenterológiai Osztály
NOT_YET_RECRUITING
Budapest
Semmelweis Egyetem. Sebeszeti, Transzplantacios es Gasztroenterologiai Klinika - Gasztroenterologiai Osztaly
RECRUITING
Budapest
Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar I. sz. Belgyogyaszati Klinika
RECRUITING
Csongrád
Italy
AOU Policlinico G. Rodolico - Ospedale San Marco - Broncopneumologia Pediatrica e Fibrosi Cistica Hospital - Public
NOT_YET_RECRUITING
Catania
Azienda Ospedaliero Universitaria Careggi - Gastroenterologia
NOT_YET_RECRUITING
Florence
Azienda Ospedaliero Universitaria Policlinico Gaetano Martino - Gastroenterologia Pediatrica e Fibrosi Cistica Academic / University Clinic
NOT_YET_RECRUITING
Messina
IRCCS Ospedale San Raffaele - Endoscopia Biliopancreatica
NOT_YET_RECRUITING
Milan
Azienda Ospedaliera Universitaria Sant'Andrea
NOT_YET_RECRUITING
Roma
Humanitas Research Hospital
NOT_YET_RECRUITING
Rozzano
Poland
Bonifraterskie Centrum Medyczne Sp. z o.o. Oddzial w Lodzi, Szpital Zakonu Bonifratrow Sw. Jana Bozego w Lodzi - Dzial Endoskopi
NOT_YET_RECRUITING
Lodz
WIP Warsaw IBD Point Profesor Kierkus
NOT_YET_RECRUITING
Pomorskie
Spain
Hospital Universitari Arnau de Vilanova de Lleida
RECRUITING
Lleida
Hospital Clinic De Barcelona - Cirug-ía General y Digestiva
NOT_YET_RECRUITING
Madrid
Hospital Universitario La Paz Hospital - University
NOT_YET_RECRUITING
Madrid
H. General de Málaga - Endocrinología
RECRUITING
Málaga
Universidad de Murcia - Hospital Universitario Virgen de la Arrixaca (HUVA)
NOT_YET_RECRUITING
Murcia
Hospital Universitario y Politecnico La Fe - Neumología
RECRUITING
Valencia
United Kingdom
Northern Ireland Clinical Research Facility (NICRF) Solo/Group Practice
NOT_YET_RECRUITING
Belfast
Greater Glasgow and Clyde
NOT_YET_RECRUITING
Glasgow
Liverpool University Hospitals NHS Foundation Trust - Royal Liverpool University Hospital
NOT_YET_RECRUITING
Liverpool
The Newcastle Upon Tyne Hospitals NHS Foundation Trust - Royal Victoria Infirmary
NOT_YET_RECRUITING
Newcastle Upon Tyne
Contact Information
Primary
Sandrine Guillot
sandrine.guillot@parexel.com
+33 (0) 6 73 64 14 16
Time Frame
Start Date: 2026-10
Estimated Completion Date: 2027-09
Participants
Target number of participants: 66
Treatments
Other: Very Low Dose Group
10 mg NHS7108 \[approximately 25,000 LU\]/main meal and snack; 25,000 LU Zenpep/main meal and snack.
Other: Low Dose Group
20 mg NHS7108 \[approximately 50,000 LU\]/main meal and 10 mg NHS7108 \[approximately 25,000 LU\]/snack; 50,000 LU Zenpep/main meal and 25,000 LU Zenpep/snack.
Other: Medium Dose Group
40 mg NHS7108 \[approximately 100,000 LU\]/main meal and 20 mg NHS7108 \[approximately 50,000 LU\]/snack; 100,000 LU Zenpep/main meal and 50,000 LU Zenpep/snack.
Other: High Dose Group
60 mg NHS7108 \[approximately 150,000 LU\]/main meal and 30 mg NHS7108 \[approximately 75,000 LU\]/snack; 150,000 LU Zenpep/main meal and 75,000 LU Zenpep/snack.
Sponsors
Collaborators: Parexel
Leads: Aimmune Nestlé Health Science US R&D, LLC

This content was sourced from clinicaltrials.gov